Drug‐induced immune‐mediated thrombocytopenia secondary to durvalumab use

Abstract

Abstract Immunotherapy is an expanding area of cancer treatment with significant promise. Despite their efficacy, checkpoint inhibitors are associated with a number of immune‐related adverse events; here, we described thrombocytopenia secondary todurvalumab.

Keywords

• ITP
• medical oncology
• pharmacokinetics
• platelets—acquired platelet disorders
• thrombocytopenia